10-KPeriod: FY2008

BIOGEN INC. Annual Report, Year Ended Dec 31, 2008

Filed February 6, 2009For Securities:BIIB

Summary

Biogen Idec Inc. (BIIB) reported strong financial performance for the year ended December 31, 2008, with total revenues reaching $4.1 billion. The company's primary revenue drivers, AVONEX (for multiple sclerosis) and RITUXAN (for lymphoma and rheumatoid arthritis), continued to show robust sales growth, contributing approximately 81% of total revenues. TYSABRI, a newer product for multiple sclerosis and Crohn's disease, demonstrated significant revenue growth, indicating increasing market acceptance despite ongoing safety monitoring. The company significantly increased its investment in research and development, spending over $1 billion to advance its pipeline, with 22 products in Phase 2 trials or beyond. This strategic investment highlights Biogen Idec's commitment to future growth through innovation in neurology, oncology, and immunology. Despite the company's strong financial position and product portfolio, it faces increasing competition and the potential impact of biosimilars on its key products. The report also details ongoing collaborations and potential future product development, providing a comprehensive view of the company's operational and strategic landscape.

Financial Highlights

56 data points
Beta

Revenue

$4.10B

90.2% Gross Margin

Net Income

$783.17M

19.1% Net Margin

EPS (Diluted)

$2.65

Total Assets

$8.48B

Cash & Equivalents

$622.38M

Free Cash Flow

$1.29B

Financial Statements
Beta
Revenue$4.10B
Cost of Revenue$401.99M
Gross Profit$3.70B
R&D Expenses$1.07B
SG&A Expenses$925.30M
Operating Expenses$2.88B
Operating Income$1.21B
Interest Expense$52.00M
Net Income$783.17M
EPS (Basic)$2.67
EPS (Diluted)$2.65
Shares Outstanding (Basic)292.33M
Shares Outstanding (Diluted)294.98M

Key Highlights

  • 1Total revenues reached $4.1 billion, driven by strong performance in AVONEX and RITUXAN.
  • 2TYSABRI demonstrated significant revenue growth, indicating increasing market acceptance.
  • 3Research and development expenses increased by 16.5% to $1.07 billion, with 22 pipeline products in Phase 2 or beyond.
  • 4The company continues to face competition in the MS market from existing and emerging therapies.
  • 5Royalty revenues from RITUXAN outside the U.S. are expected to decrease significantly starting in the latter half of 2009 due to patent expirations.
  • 6Biogen Idec completed a significant tender offer in July 2007, repurchasing over 56 million shares.
  • 7The company is actively managing its intellectual property portfolio, with key patents for RITUXAN expiring between 2015 and 2018.

Frequently Asked Questions

Biogen Idec's primary revenue drivers were AVONEX, used to treat multiple sclerosis, and RITUXAN, used for certain B-cell non-Hodgkin's lymphoma and rheumatoid arthritis. These two products accounted for approximately 81% of the company's total revenues in 2008.

TYSABRI showed significant revenue growth in 2008, reaching $588.6 million. This growth indicates increasing market acceptance for treating relapsing MS and Crohn's disease. However, the company continues to monitor the known side effect of PML (progressive multifocal leukoencephalopathy) and is developing protocols to mitigate risks.

Biogen Idec's long-term growth strategy relies on the successful development and commercialization of its research and development pipeline. The company significantly increased R&D spending in 2008 to over $1 billion, focusing on novel therapeutics in neurology, oncology, and immunology. This includes actively managing 22 pipeline products in Phase 2 trials or further along.

Key risks include substantial dependence on AVONEX and RITUXAN revenues, the market acceptance and safety profile of TYSABRI, intense competition from other biotechnology and pharmaceutical companies, potential emergence of biosimilars, and regulatory and reimbursement challenges within the healthcare industry. Additionally, the company faces risks related to patent expirations, particularly for RITUXAN royalties outside the U.S. starting in late 2009.